ABOUT US

OUR COMPANY

AIMEDBIO combines AI (artificial intelligence) technology with the field of MED (medicine) to practice data-driven precision medicine. We pursue after attainable treatment solutions to patients with refractory brain disease, including cancer, in hopes of providing better quality of life.

Aimed.png

VISION

MISSION 

I  Patient-centered pharmaceutical company

I  Developing innovative new precision therapeutics for brain-disease and -tumor

t_history.png

2018.08

AIMEDBIO Inc. was founded

2019.01

In-licensed the patents and resources from Samsung Medical Center

2019.04

Collaboration deal with a global big pharmaceutical company

2019.08

AVATAMED PTE Ltd., a spin-off company from 
A-star founded in Singapore

2019.09

Received the certification of venture business

2019.12

AIMEDBIO R&D Center OPEN

2020.04

Genotwin, a spin-off company from

Columbia University founded in New York

2020.06

AIMEDBIO initiates a joint lab with CBMED to collaborate on precision medicine drug screening project

2020.07

Discovery of AMB003, a novel antibody potentially active in brain cancer
therapy was filed for a patent

2020.09

Licensed-in a brain-specific payload from Samsung Medical Center & Sejong University

Visit CBmed

Visit Genotwin

Visit AVATAMED

Download paper